Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 September 28, 2023 Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering September 28, 2023 Madrigal Pharmaceuticals Announces Proposed Public Offering September 14, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 13, 2023 Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis September 11, 2023 Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer August 8, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results July 17, 2023 Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis June 30, 2023 Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis June 22, 2023 Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™ June 6, 2023 Madrigal Pharmaceuticals Supports International NASH Day on June 8 Pagination Current page 1 Page 2 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 September 28, 2023 Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering September 28, 2023 Madrigal Pharmaceuticals Announces Proposed Public Offering September 14, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 13, 2023 Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis September 11, 2023 Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer August 8, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results July 17, 2023 Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis June 30, 2023 Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis June 22, 2023 Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™ June 6, 2023 Madrigal Pharmaceuticals Supports International NASH Day on June 8 Pagination Current page 1 Page 2 Next page
September 14, 2023 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 13, 2023 Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
August 8, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
July 17, 2023 Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 30, 2023 Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 22, 2023 Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
